276 related articles for article (PubMed ID: 31615436)
1. Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review.
Ishihara A; Hatakeyama S; Suzuki J; Amano Y; Sasahara T; Toshima M; Morisawa Y
BMC Infect Dis; 2019 Oct; 19(1):848. PubMed ID: 31615436
[TBL] [Abstract][Full Text] [Related]
2. Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma.
Yokota K; Yotsumoto M; Muramatsu T; Saito M; Kamikubo Y; Ichiki A; Chikasawa Y; Bingo M; Hagiwara T; Amano K; Fukutake K
J Infect Chemother; 2020 Feb; 26(2):289-291. PubMed ID: 31537471
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
[TBL] [Abstract][Full Text] [Related]
4. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
5. Laryngeal Kaposi's Sarcoma Complicated by the Immune Reconstitution Inflammatory Syndrome in an HIV-infected Patient.
Kato H; Yanagisawa N; Morioka H; Sasaki S; Sekiya N; Suganuma A; Imamura A; Ajisawa A
Intern Med; 2016; 55(8):1001-5. PubMed ID: 27086821
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.
Ramaswami R; Uldrick TS; Polizzotto MN; Wyvill KM; Goncalves P; Widell A; Lurain K; Steinberg SM; Figg WD; Tosato G; Whitby D; Yarchoan R
Clin Cancer Res; 2019 Jul; 25(14):4238-4247. PubMed ID: 30979736
[TBL] [Abstract][Full Text] [Related]
7. Necrotizing leg gangrene from invasive cutaneous Kaposi sarcoma, reversed by pegylated liposomal doxorubicin.
Goff CB; Stapleton A; Aboulafia DM; Dasanu CA
J Oncol Pharm Pract; 2022 Jun; 28(4):1003-1008. PubMed ID: 35037777
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study.
Dalu D; Fasola C; Ammoni L; De Francesco D; Cona MS; Rota S; Ferrario S; Gambaro A; Tosca N; Piva S; La Verde N
J Chemother; 2021 Sep; 33(5):342-347. PubMed ID: 34060438
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of an HIV-positive patient with unmasking Kaposi's sarcoma immune reconstitution inflammatory syndrome.
Speicher DJ; Sehu MM; Johnson NW; Shaw DR
J Clin Virol; 2013 Jul; 57(3):282-5. PubMed ID: 23578530
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
Cianfrocca M; Lee S; Von Roenn J; Tulpule A; Dezube BJ; Aboulafia DM; Ambinder RF; Lee JY; Krown SE; Sparano JA
Cancer; 2010 Aug; 116(16):3969-77. PubMed ID: 20564162
[TBL] [Abstract][Full Text] [Related]
11. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
12. [Profile of Kaposi sarcoma patients in the competence network HIV/AIDS].
Klingenberg RE; Esser S; Brockmeyer NH; Michalik C; Skaletz-Rorowski A; Potthoff A;
Hautarzt; 2018 Feb; 69(2):143-148. PubMed ID: 29101417
[TBL] [Abstract][Full Text] [Related]
13. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
14. Kaposi Sarcoma of the eyelid as an initial manifestation of AIDS.
Teixeira AI; Neno M; Badura R; Borges-Costa J; Filipe PL
Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617725
[TBL] [Abstract][Full Text] [Related]
15. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
Duggan ST; Keating GM
Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391
[TBL] [Abstract][Full Text] [Related]
17. Total resolution of ocular Kaposi sarcoma with different treatment approaches - a case series and review of literature.
Yeak J; Iqbal T; Zahari M; Ismail F
Int J STD AIDS; 2019 Jul; 30(8):802-809. PubMed ID: 31046617
[No Abstract] [Full Text] [Related]
18. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
[TBL] [Abstract][Full Text] [Related]
19. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin.
Hengge UR; Esser S; Rudel HP; Goos M
Eur J Cancer; 2001 May; 37(7):878-83. PubMed ID: 11313176
[TBL] [Abstract][Full Text] [Related]
20. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
